112 results on '"Guin, Sunny"'
Search Results
2. Supplementary Table 1 from RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer
3. Supplementary Figure and Table Legends from RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer
4. Supplementary Figure 1 from RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer
5. Supplementary Figure 3 from RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer
6. Supplementary Table 2 from RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer
7. Supplementary Figure 2 from RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer
8. Supplemental Figure Legends from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
9. Supplemental Table 4 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
10. Supplemental Figures 1-5 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
11. Supplemental Table 5 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
12. Supplemental Table 3 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
13. Supplemental Table 2 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
14. Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape
15. Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience
16. Genomic case report of a low grade bladder tumor metastasis to lung
17. Contributions of KRAS and RAL in Non–Small-Cell Lung Cancer Growth and Progression
18. QOPI Clinical Informatics: A digital platform to enable real-time quality reporting, clinical decision support, and rapid learning.
19. Landscape of tumor genetic testing and targeted therapies over an eight-year span in a rural population.
20. Analysis of genomic alterations and treatment landscape in patients with advanced tumors using real-world data for precision oncology.
21. MP27-10 CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING FOR PROSTATE CANCER IN THE CONTEXT OF A CHANGING TREATMENT LANDSCAPE
22. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma
23. Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape.
24. Discovery and characterization of small molecules that target the GTPase Ral
25. Docetaxel vs. Novel Hormonal Agent for Upfront Management of De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Report of a Single-Center Experience
26. Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction.
27. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase
28. Role in Tumor Growth of a Glycogen Debranching Enzyme Lost in Glycogen Storage Disease
29. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers with Lung Adenocarcinoma
30. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells
31. Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein
32. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
33. Abstract 3449: AGL loss promotes anchorage independent growth of non-small cell lung cancer by activating FAK
34. Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth
35. Additional file 1: Table S1. of CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL)
36. Abstract 1545: Loss of glycogen debranching enzyme (AGL) promotes rapid growth of non-small cell lung cancer cells
37. Involvement of glycogen debranching enzyme in bladder cancer
38. CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL)
39. Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
40. Immunoliposome based targeting of RON receptor tyrosine kinase - A novel approach for epithelial cancer treatment
41. Abstract 4949: HAS2 is a critical effector for AGL mediated regulation of tumor growth
42. Targeting glycogen metabolism in bladder cancer
43. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer
44. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer
45. Abstract 2138: Tumorigenic and migratory potential of Ral GTPases in non-small cell lung cancers
46. Sustained Expression of the RON Receptor Tyrosine Kinase by Pancreatic Cancer Stem Cells as a Potential Targeting Moiety for Antibody-Directed Chemotherapeutics
47. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells
48. Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein
49. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
50. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.